NCT06528262 - Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

August 5, 2026

Study Completion Date

August 5, 2026

Conditions

Atrial Fibrillation

Interventions

DRUG

Enavogliflozin

Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days

DRUG

Placebo

Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days

Trial Locations (1)

Unknown

Severance Hospital, Seoul